Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million).
Kreos Capital is a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. The new debt facility will be available to Botanix for working capital purposes for the commercialisation of Sofdra™, as well as other platform expansion opportunities. H.C. Wainwright & Co. acted as origination, structuring and placement agent for the transaction.
https://botanixpharma.com/wp-content/uploads/BOT-Euroz-Hartleys.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-05-13 04:15:572025-05-13 04:15:58Euroz Hartleys Research Report | BOT: All Bark No Bite
Botanix CEO Howie McKibbon spoke with Stockhead’s Tylah Tully about Botanix’s elevation to the S&P/ASX 300 index, and the Company’s ambitions to become a global leader in dermatology innovation.
Here’s an excerpt:
“It’s a great honour and validation to join this league and a validation of the work that we’ve done and of our growth as a company. We’ll continue to focus on building Botanix to become the world’s largest and most innovative dermatology company.”
https://botanixpharma.com/wp-content/uploads/Screenshot-2025-03-17-at-9.04.41-am.png6741203Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-03-16 22:04:292025-03-16 22:05:42Stockhead | Interview with Howie McKibbon
Botanix CEO Howie McKibbon joined Sharecafe’s Abby Phillips this week to provide an update on the Company’s recent US launch of Sofdra™ and its commercial progress.
Howie shared insights on Botanix’s experienced sales team, momentum in securing contracts with payer organizations covering over 90% of commercially insured lives plus Medicaid, and early results from a digital marketing campaign that’s driving awareness and converting online interest into prescriptions.
https://botanixpharma.com/wp-content/uploads/Unknown-1.png19363450Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-03-16 21:57:582025-03-24 03:01:53Sharecafe | Interview with Howie McKibbon
Botanix Executive Director Matt Callahan spoke with Sharecafe to discuss the Company’s recent US launch of Sofdra™.
Matt noted that early prescription growth is tracking to expectations only six weeks into the launch, highlighting Botanix’s unique platform that improves patient refill rates while enhancing profitability.
https://botanixpharma.com/wp-content/uploads/Sharecafe-Matt-Callahan.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-03-16 21:55:372025-03-16 21:55:38Sharecafe | Interview with Matt Callahan
Botanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index as part of the March 2025 quarterly rebalance.
The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap components of the S&P/ASX Index Series.
To be considered for inclusion, a company must meet a minimum market capitalization, typically around A$100 million, based on average daily market cap over the last six months, and have sufficient liquidity; meaning the stock must be actively traded in adequate volume to be considered institutionally investable. The index is regularly reviewed, and companies are added or removed to rebalance twice annually to reflect changes in market capitalization and liquidity.
https://botanixpharma.com/wp-content/uploads/ASX-300.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-03-16 21:17:142025-03-16 21:17:44Botanix included in ASX 300 Index
Botanix signs debt facility with Kreos Capital
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million).
Kreos Capital is a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. The new debt facility will be available to Botanix for working capital purposes for the commercialisation of Sofdra™, as well as other platform expansion opportunities. H.C. Wainwright & Co. acted as origination, structuring and placement agent for the transaction.
Click to read the ASX release.
Euroz Hartleys Research Report | BOT: All Bark No Bite
/in Featured, Latest News, News /by Haley ChartresEuroz Hartleys has published a research note on Botanix maintaining a price target of $0.80.
The report addresses President Trump’s recent executive order on drug pricing and concludes it will have “little to no impact” on BOT or Sofdra™.
Click here to read the full report.
Stockhead | Interview with Howie McKibbon
/in Featured, Latest News, News, Videos /by Haley ChartresBotanix CEO Howie McKibbon spoke with Stockhead’s Tylah Tully about Botanix’s elevation to the S&P/ASX 300 index, and the Company’s ambitions to become a global leader in dermatology innovation.
Here’s an excerpt:
“It’s a great honour and validation to join this league and a validation of the work that we’ve done and of our growth as a company. We’ll continue to focus on building Botanix to become the world’s largest and most innovative dermatology company.”
Sharecafe | Interview with Howie McKibbon
/in Featured, Latest News, News /by Haley ChartresBotanix CEO Howie McKibbon joined Sharecafe’s Abby Phillips this week to provide an update on the Company’s recent US launch of Sofdra™ and its commercial progress.
Howie shared insights on Botanix’s experienced sales team, momentum in securing contracts with payer organizations covering over 90% of commercially insured lives plus Medicaid, and early results from a digital marketing campaign that’s driving awareness and converting online interest into prescriptions.
Sharecafe | Interview with Matt Callahan
/in Featured, Latest News, News /by Haley ChartresBotanix Executive Director Matt Callahan spoke with Sharecafe to discuss the Company’s recent US launch of Sofdra™.
Matt noted that early prescription growth is tracking to expectations only six weeks into the launch, highlighting Botanix’s unique platform that improves patient refill rates while enhancing profitability.
Botanix included in ASX 300 Index
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index as part of the March 2025 quarterly rebalance.
The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap components of the S&P/ASX Index Series.
To be considered for inclusion, a company must meet a minimum market capitalization, typically around A$100 million, based on average daily market cap over the last six months, and have sufficient liquidity; meaning the stock must be actively traded in adequate volume to be considered institutionally investable. The index is regularly reviewed, and companies are added or removed to rebalance twice annually to reflect changes in market capitalization and liquidity.
Click here to see the ASX announcement